Interrogating the TME with AI: How standardizing the analysis of tumor microenvironment with AI could advance cancer treatment and drug development

Dr. Mike Montalto, PhD, PathAI Chief Scientific Officer, explores the potential of artificial intelligence to  standardize the analysis of tumor microenvironment (TME) which will enable researchers to better understand treatment pathways, identify novel biomarkers, and advance drug development.